Kornimate/medical-research-clean huggingface dataset:
pregablin for anxiety-comorbidity in patients with schizophrenia

Conditions: Schizophrenia; Anxiety-comorbidity to Schizophrenia

Summary: the pacs study aims to investigate the efficacy and tolerability of pregabalin for schizophrenic patients that suffer from comorbid anxiety. the study design is an 8 week flexible dosage, randomized placebo controlled. the study population is patients diagnosed with icd-10 schizophrenia and age 18-65. patients are recruited from outpatient clinics from entire denmark.


Eligibility criteria:
inclusion criteria: * ages 18-65 years * an icd-10 schizophrenia diagnosis f20.0-20.3 or f20.9 * stable dosage of psychotropic 4 weeks before inclusion * hamilton anxiety scale total score \> 15 * positive and negative syndrome scale for schizophrenia total score \< 70 * the calgary depression scale for schizophrenia total score \< 10 * fertile women: contraception during the trial * s-creatinin within normal reference range * signed informed consent and power of attorney exclusion criteria: * significant substance abuse * qtc \> 480 milliseconds * severe dysregulated diabetes * for women: pregnancy or breast-feeding * confinement in accordance with the danish law of psychiatry * concrete suicidally * known hypersensitivity or allergic reaction to the active ingredient of the drug

Keywords: anxiety-comorbidity to schizophrenia double-blinded randomized placebo controlled trial pregabalin
retrograde saline irrigation during supine mini percutaneous nephrolithotomy

Conditions: Renal Stone; Supine Mini Percutaneous Nephrolithotomy

Summary: this minimally invasive surgery allows us to remove kidney stones through tiny incisions and provides patients with quicker and smoother recoveries


Eligibility criteria:
inclusion criteria: * age above 18 years * renal stones exclusion criteria: * age less than 18 years

Keywords: supine
the effect of probiotics on non alcoholic fatty liver disease

Conditions: Liver Disease

Summary: nonalcoholic fatty liver disease (nafld) has been suggested to be the most common cause of chronic liver disease in the general population in the western world. in advanced stages of nafld, steatohepatitis (nash) develops characterized by: steatosis, inflammation, and fibrosis progressing to cirrhosis in some patients. the knowledge of the role of small intestinal bacterial overgrowth (sibo) in the pathogenesis of nash has led to the proposal of probiotics as a therapeutic strategy for this disorder.

probiotics may interfere with the development of nash by several mechanisms. data from an uncontrolled clinical trial in nash patients show promising results, with improvement of liver enzymes in treated patients. research goals: a. to assess the degree of sibo in nafld patients vs. healthy controls. b. to evaluate the effect of probiotics vs. placebo on sibo in nafld patients. c. to evaluate the effect of probiotics vs. placebo on disease severity (inflammation, steatosis, and fibrosis) in nafld patients.

Eligibility criteria:
inclusion criteria: * controls- healthy volunteers, male and female, above 18 years. * nafld group - patients with histological proven nafld, male and female, above 18 years. exclusion criteria: * controls * those who will be found to have fatty liver in abdominal ultra sound * any participant who will take antibiotics for any indication for more than 1 week during the study period or before recruitment to the study * any participant who had lost more than 10% of baseline body weight during the study period. * nafld group * those who will be found to have any concomitant liver disease (i.e., hbv/hcv/hiv/ebv/cmv infection * autoimmune hepatitis * metabolic liver disease: wilson's disease, cholestatic liver disease: pbc/psc, etc.) * any participant who will take antibiotics for any indication for more than 1 week during the study period or before recruitment to the study * any participant who had lost more than 10% of baseline body weight during the study period

Keywords: non alcoholic fatty liver disease non alcoholic steatohepatitis small bowel bacterial overgrowth probiotics patients with non alcoholic fatty liver disease
analysis of differential proteins and maternal influencing factors of septic shock in neonates

Conditions: Neonatal Disease

Summary: 1. explore 32 weeks of premature infants or maternal pregnancy infection of newborn septic shock maternal influence factors. 2. through maternal blood samples before delivery and labor cord blood sample screening and septic shock related proteomics analysis, explore the relationship between the difference protein and septic shock and prognosis, and explore the pathway mechanism, in order to prevent and reduce the occurrence of septic shock in premature infants

the birth cohort was established with 32 weeks of premature infants or maternal infection during pregnancy.whole proteomic analysis was performed on maternal blood before delivery and umbilical cord blood samples at delivery,and screscreen differential proteins associated with septic shock and classify these proteins as leak factor into exposed and non-exposed groups for cohort study.the incidence and mortality of shock,severe brain injury and bpd in the two groups were compared, and the mechanism of the differential protein was studied to provide early warning in children with septic shock.

Eligibility criteria:
inclusion criteria: * all ≤32-week premature infants admitted to our nicu; all newborns delivered by the mother infected during pregnancy exclusion criteria: * not delivered in our hospital; congenital cardiovascular development malformation, fetal malformation, genetic metabolic diseases, etc
egg consumption and muscular adaptations

Conditions: Hypertrophy

Summary: eggs may be a viable alternative to various types of supplemental proteins given its similar ratings on various measures of dietary protein quality. the investigators hypothesis is that whole eggs would create a greater improvement in skeletal regulatory markers, hormonal responses and body composition than egg white ingestion in resistance-trained men.

the aim of this investigation was to compare the effects of whole egg versus egg white ingestion (daily and after training sessions) during 12 weeks of resistance training on skeletal muscle regulatory markers, hormonal responses and body composition in resistance-trained men. specific aims of the study are to: to investigate the extent to which both whole egg and egg white ingestion will improve anabolic factors, fat free mass, fat mass and decrease catabolic markers after 12 weeks of resistance training in resistance-trained men.

Eligibility criteria:
inclusion criteria: * performing resistance training at least three times a week for 1 year prior to the start of the study * not taking any dietary supplements or medications for at least 1 year prior to the start of the study * no known medical issues * no alcohol consumption or smoking for at least 1 year prior to the start of the study * no egg allergy/sensitivity. exclusion criteria: * non-willingness to continue nutritional or exercise protocols * participation in exercise other than the prescribed resistance training program * consumption of dietary supplement (other than egg) during the study period * missing more than one resistance training session or post-exercise egg consumption throughout the study period
lawrence latino diabetes prevention project

Conditions: Metabolic Syndrome

Summary: the lawrence latino diabetes prevention project (lldpp) is a community-based translational research study which aims to reduce the risk of diabetes among latinos who have a \>30% probability of developing diabetes in the next 7.5 years per a predictive equation. the project was conducted in lawrence, massachusetts; a predominantly caribbean-origin urban latino community. individuals were identified primarily from a community health center's patient panel, screened for study eligibility, randomized to either a usual care or a lifestyle intervention condition, and followed for one year.

the group format of the intervention included 13 group sessions complemented by 3 individual home contacts over one year and was implemented by individuals from the community with training and supervision by a clinical research nutritionist and a behavioral psychologist. study measures included demographics, stern predictive equation components (age, gender, ethnicity, fasting glucose, systolic blood pressure, hdl-cholesterol, body mass index, and family history of diabetes), glycosylated hemoglobin, dietary intake, physical activity, depressive symptoms, social support, and quality of life. body weight was measured at baseline, 6-months, and one-year; all other measures were assessed at baseline and one-year. all surveys were orally administered in spanish.

Eligibility criteria:
inclusion criteria: * is latino/hispanic; * has a 7.5 year likelihood of becoming diabetic of greater than or equal to 30% as predicted by the stern formula; * is greater than or equal to 25 years of age; * has a bmi greater than or equal to 24 kg m2. exclusion criteria: * an inability or unwillingness to give informed consent; * has clinically diagnosed diabetes, or a fasting blood sugar of greater than or equal to 126 mg/dl; * plans to move out of the area within the study period; * has a psychiatric illness which limits ability to participate; * has no telephone; * is unable to walk unaided, or cannot walk five city blocks (1/4 mile) without stopping; * is not cleared for the pa component by the pt's glfhc primary care provider; * has a medical conditions likely to limit lifespan; * is on medications or has a medical condition that interfere with the assessment for diabetes.

Keywords: metabolic syndrome latino health community participatory research translational research
effect of core stability excercises program on reaching in children with cerebral palsy

Conditions: Cerebral Palsy

Summary: purpose of the study: to evaluate effect of core stability exercises program on upper limb reaching in children with spastic hemiparetic cerebral palsy.

thirty spastic hemiparetic cerebral palsied children of both sexes will be selected from general hospitals and private centers in el-minia government with the following criteria: 1. the age of the selected children ranged from 3 to 6 years old. 2. degree of spasticity is ranging from 1 to 1+, according to modified ashworth scale 3. children in study group will be treated using core stability exercises program in addition to traditional program and children in the control group will be treated using traditional physical therapy program. 4. trunk control measurement scale and pediatric reach test will be used to evaluate each child individually before and after 6 successive weeks of treatment, three times per week.

Eligibility criteria:
inclusion criteria: 1. the age of the selected children ranged from 3 to 6 years old. 2. degree of spasticity is ranging from 1 to 1+, according to modified ashworth scale(bohannon and smith, 1987). 3. children with hemiparetic cerebral palsy exclusion criteria: 1. fructures and fixed deformities
continuous treatment study of topiramate in migraine participants

Conditions: Migraine

Summary: the purpose of this study is to evaluate the safety and efficacy of topiramate in participants with migraine (type of severe headache that occurs periodically and is often associated with nausea, vomiting and constipation or diarrhea) who completed the jns019-jpn-02 study.

this is an open-label (all people know the identity of the intervention), multicenter (conducted in more than one center), dose-titration (dose escalation/reduction) study of topiramate in participants with migraine. this study is a continuous study for the participants who were enrolled in the jns019-jpn-02 study. participants who completed the jns019-jpn-02 study will receive treatment for 52 weeks starting at visit 4 of the jns019-jpn-02 study. the present study will consist of 3 weeks of transfer period (during this period the dose titration will take place and along with dose titration the new treatment will be initiated at 25 milligram per day \[25mg/day\]), continuous treatment period (32 weeks), exit period (up to 3 weeks) and follow-up period (4 weeks). participants in the continuous treatment period will receive topiramate tablets orally in the dose range of 50 mg/day to 100 mg/day. dose can be increased or decreased as per investigator's discretion. the maximum daily dose will be 200 mg/day. efficacy will be primarily evaluated by change from baseline in the number of monthly migraine attacks in continuous treatment period. participants' safety will be monitored throughout the study.

Eligibility criteria:
inclusion criteria: - participants who completed the jns019-jpn-02 study or discontinued the study at week 4 or after in fixed-dose period because of insufficient efficacy exclusion criteria: * participants who discontinued the jns019-jpn-02 study for an adverse event unrelated to the underlying disease * participants judged unfavorable to be transferred to this study because of the safety assessments in the jns019-jpn-02 study * pregnant (carrying an unborn baby) female participants * other participants who were considered ineligible as per investigator's discretion

Keywords: migraine topiramate
efficacy and safety of a triptorelin 6-month formulation in patients with advanced prostate cancer

Conditions: Prostatic Neoplasm

Summary: efficacy and safety of a triptorelin 6-month formulation in patients with advanced prostate cancer. it was assumed that during the study treatment \>90% of the patients would achieve and maintain castrate levels of serum testosterone.

efficacy of triptorelin treatment on gonadotropin (lh) stimulation from hypophysis, as well as on the psa (prostate specific antigen) levels and safety laboratory parameters. the triptorelin pharmacokinetics and testosterone pharmacodynamics were assessed in a subset of 15 patients.

Eligibility criteria:
inclusion criteria: * histologically or cytologically proven prostate cancer. * the prostate cancer should be staged t3-4nxmx or txn1-3mx or txnxm1 according to the tnm classification or the patient should have rising psa after failed local therapy and be candidate for androgen deprivation therapy. * serum testosterone levels \>5 nmol/l. * karnofsky performance index \>40. * expected survival \> 18 months. * absence of another malignancy, other than local dermatological, for the previous 5 years. * signed informed consent before entry into the study. exclusion criteria: * prior hormonal treatment for prostate cancer within 6 months prior to study start. * use of finasteride (proscar®) or dutasteride (avodart®/avolve®) within 2 months prior to study start. * presence of another neoplastic lesion or brain metastases. * prior hypophysectomy or adrenalectomy. * known or suspicion of vertebral metastases with risk of spinal compression. * severe kidney or liver failure (creatinine \> 2 times the upper normal limit, asat and alat \>3 times the upper normal limit). * any concomitant disorder or resulting therapy that is likely to interfere with patient compliance or with the study in the opinion of the investigator. * participation in another study with an experimental drug within 3 months before study start or within 5 drug half-lives of the investigational drug (whichever is the longer). * known hypersensitivity to any of the test materials or related compounds. * known active use of recreational drug or alcohol dependence in the opinion of the investigator. * any current use or use within 6 months prior to treatment start of medications which are known to affect the metabolism and/or secretion of androgenic hormones: ketoconazole, aminoglutethimide, oestrogens, and progesterone. * use of systemic or inhaled corticosteroids (topical application permitted). * use of anticoagulants: heparin and coumarine derivatives (acetylsalicylic acid permitted). * inability to give informed consent or to comply fully with the protocol.

Keywords: triptorelin, 6-month formulation, advanced prostate cancer
autonomic differences in heart rate variability between healthy and chronic low back pain subjects

Conditions: Chronic Low Back Pain (CLBP); Heart Rate Variability; Autonomic Nervous System Dysfunction

Summary: this study aims to evaluate the autonomic differences in heart rate variability (hrv) between healthy individuals and those with chronic low back pain. by analyzing hrv parameters, such as time-domain, frequency-domain, and non-linear metrics, this cross-sectional study seeks to explore the impact of chronic pain on the autonomic nervous system. the study will provide insights into parasympathetic and sympathetic modulation and its potential relationship with chronic pain symptoms. participants include healthy adults and individuals with chronic low back pain aged 18-65.


Eligibility criteria:
inclusion criteria: * adults aged between 18 and 65 years. for the chronic low back pain group: * diagnosis of chronic low back pain lasting at least three months. * a minimum pain intensity of 3/10 on the numerical pain rating scale (nprs). for the healthy group: * absence of any chronic or acute pathology. * no regular medication that could alter autonomic nervous system function. * no episodes of low back pain in the past six months. exclusion criteria: * presence of uncontrolled neurological or cardiac disorders. * use of medications that could influence autonomic function or pain perception (e.g., opioids, antidepressants, benzodiazepines, anti-inflammatory drugs, beta-blockers) within two weeks prior to the study. * body mass index (bmi) equal to or greater than 30 kg/m².
elders preferences in care decisions

Conditions: Early Detection of Cancer; Colon Cancer; Decision Making; Patient-Centered Care

Summary: the purpose of this research study is to explore ways to improve appropriate colorectal cancer (crc) screening in the elderly by attempting to target screening in those most likely to benefit and avoiding screening in those least likely to benefit.

the investigators propose a randomized controlled trial at the patient level to determine the efficacy of a colorectal cancer screening decision support intervention for patients ages 70 to 84 within a clinical setting. the investigators hypothesize that the use of the intervention will prepare patients for individualized decision making with their providers and result in an improvement in appropriate crc screening decisions and screening outcomes. to assess appropriate crc screening decisions and screening, the investigators will use a classification scheme derived from the literature based on age and the charlson comorbidity index. using this scheme, appropriate screening will include screening for those in the best health because they are likely to benefit, no screening for those in the worst health because they are unlikely to benefit, and evidence of a discussion about crc screening for those in the intermediate health group because the benefit is unclear.

Eligibility criteria:
inclusion criteria: * men and women ages 70 to 84 * not up to date with colon cancer screening or surveillance exclusion criteria: * men and women younger than 70 years of age or older than 84 * history of colorectal cancer * inflammatory bowel disease

Keywords: colon cancer screening decision support interventions health status patient-centered care age randomized controlled trial double blind unc
evaluation of respiratory mechanics and functionality in patients with chronic obstructive pulmonary disease

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: to associate a lean mass, peripheral muscle strength, kinematic thoracic-abdominal, respiratory metabolic response, mobility and diaphragmatic thickness, verifying its relation with the obstruction level of copd

individuals with copd present restriction in their daily lives due to changes and bodily disorders promoted by the disease, such as changes in types of muscle fibers and chronic inflammatory process, causing a low level of physical activity and quality of life, besides being closely related to the need for hospitalizations and increased mortality. a cross-sectional study with a convenience sample was performed at the laboratory of cardiopulmonary physiotherapy of the federal university of pernambuco during the period from december 2016 to february 2018. as measurements of body composition were performed with a bio-balance scale, evaluation of the peripheral muscle strength will be used the dynamometer, a load cell and electromyography, a kinematic thoracic-abdominal will be measured by optoelectronic plethysmography, a respiratory metabolic response will be verified during the 6-minute walk test using the gas analyzer, and for evaluation of mobility and diaphragmatic thickness are used on ultrasound associated with pneumotachograph.

Eligibility criteria:
inclusion criteria: * young adults, adults and elderly subjects exclusion criteria: * others respiratory diseases; * heart diseases; * those who are in some previous training program or rehabilitation;

Keywords: body composition ultrasound chronic pulmonary obstructive disease respiratory muscles
adverse reactions and efficacy of fixed-dose combination anti-tuberculosis (tb) drugs

Conditions: Tuberculosis

Summary: the fixed-dose combinations (fdc) with two or more antituberculous drugs in one capsule or tablet are available to prevent the development of drug resistance. however, the fixed-dose combination regimen is not consistent with the dosages that are usually given. the present available fdc chemotherapy (rifater) for pulmonary tuberculosis that is used in taiwan has a higher ratio of isoniazid to rifampin and pyrazinamide. the higher risk of drug toxicity and adverse reactions when using fixed-dose combinations regimen should be considered. the aim of the present study is to compare the toxicity between using fdc regimen (rifater/rifinah) in taiwan and single drugs in the treatment of newly diagnosed pulmonary tuberculosis. the investigators also evaluate the efficacy of two regimens and determine the incidence of discontinuation of tb drugs and the predisposed factors between two regimens.


Eligibility criteria:
inclusion criteria: 1. newly diagnosed pulmonary tb and extrapulmonary tb patients 2. no previous anti-tb drugs treatment 3. age≥18years old exclusion criteria: 1. expected life \< 6months 2. baseline ast/alt \> 3x upper limit of normal (uln) 3. age \<18years old

Keywords: fix-dose combination anti-tb drug adverse effect efficiency
endoscopic mucosal resection with circumferential incision for colorectal neoplasms

Conditions: Endoscopic Mucosal Resection With Circumferential Incision

Summary: this is a prospective randomized trial to improve the results of treatment of patients with colorectal neoplasms.

generally, endoscopic mucosal resection (emr) and endoscopic submucosal dissection (esd) are the methods of choice for the removal of benign and early malignant neoplasms of the colon. however, there are certain difficulties in terms of the emr technique - this is an increase in the frequency of fragmentation with a lesion size of more than 20 mm, which in turn increases the risk of recurrence; with regard to esd technique, this is a long procedure time; high incidence of complications; significant time required for teaching the technique; technical difficulties. in this regard, it is worth paying attention to the method of "endoscopic mucosal resection with circumferential mucosal incision" (c-emr). this method deserves interest due to the fact that it allows more often to perform en-block resections in comparison with the classical method of endoscopic mucosal resection (emr - endoscopic mucosal resection); technically easier to do; takes a short procedure time.

Eligibility criteria:
inclusion criteria: * patients with benign colon neoplasms without signs of deep invasion (i, ii, iiil and iv type according to kudo, i and ii type according to sano) * the size of the neoplasm is from 20 mm to 30 mm * patient for treatment exclusion criteria: * unsatisfactory tumor lifting * refusal of the patient from research at any stage of treatment

Keywords: c-emr endoscopic treatment colorectal neoplasm circumferential incision